Delta 9 Cannabis Inc. operates as an integrated cannabis company. More Details
Slightly overvalued with limited growth.
Share Price & News
How has Delta 9 Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: DN exceeded the Canadian Pharmaceuticals industry which returned -18.6% over the past year.
Return vs Market: DN underperformed the Canadian Market which returned -4% over the past year.
Price Volatility Vs. Market
How volatile is Delta 9 Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDelta 9 Cannabis (TSE:DN) Takes On Some Risk With Its Use Of Debt
5 months ago | Simply Wall StDid Changing Sentiment Drive Delta 9 Cannabis' (TSE:DN) Share Price Down A Worrying 68%?
6 months ago | Simply Wall StWe're Not So Sure You Should Rely on Delta 9 Cannabis's (TSE:DN) Statutory Earnings
Is Delta 9 Cannabis undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DN (CA$0.58) is trading below our estimate of fair value (CA$2.45)
Significantly Below Fair Value: DN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DN is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: DN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DN's PB Ratio (1.4x) is in line with the CA Pharmaceuticals industry average.
How is Delta 9 Cannabis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if DN's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if DN's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DN's revenue (31% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: DN's revenue (31% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DN's Return on Equity is forecast to be high in 3 years time
How has Delta 9 Cannabis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DN is currently unprofitable.
Growing Profit Margin: DN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DN is unprofitable, but has reduced losses over the past 5 years at a rate of 43% per year.
Accelerating Growth: Unable to compare DN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).
Return on Equity
High ROE: DN has a negative Return on Equity (-1.68%), as it is currently unprofitable.
How is Delta 9 Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: DN's short term assets (CA$32.2M) exceed its short term liabilities (CA$14.6M).
Long Term Liabilities: DN's short term assets (CA$32.2M) exceed its long term liabilities (CA$21.3M).
Debt to Equity History and Analysis
Debt Level: DN's debt to equity ratio (61.6%) is considered high.
Reducing Debt: Insufficient data to determine if DN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Delta 9 Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Arbuthnot (30 yo)
Mr. John William Arbuthnot, IV, also known as John, has been Chief Executive Officer at Delta 9 Cannabis Inc. since October 31, 2017. Mr. Arbuthnot is Co-founder and Vice-President and Responsible Person i ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD127.18K) is about average for companies of similar size in the Canadian market ($USD171.35K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|CFO & Controller||2.08yrs||CA$126.53k||0.24% |
|Chief Technology Officer||no data||no data||no data|
|Vice President of Corporate Affairs||no data||no data||no data|
|Senior Executive Assistant||2.75yrs||no data||no data|
Experienced Management: DN's management team is considered experienced (2.9 years average tenure).
|Independent Director||2.08yrs||CA$48.00k||no data|
|Independent Director||3yrs||CA$48.00k||no data|
|Independent Director||2.92yrs||CA$48.00k||0.94% |
Experienced Board: DN's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.
Delta 9 Cannabis Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Delta 9 Cannabis Inc.
- Ticker: DN
- Exchange: TSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$52.318m
- Shares outstanding: 90.20m
- Website: https://www.delta9.ca
Number of Employees
- Delta 9 Cannabis Inc.
- P.O. Box 68096
- Osborne Village
- R3L 2V9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DN||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Nov 2017|
|VRND.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Nov 2017|
|V5D1||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Nov 2017|
|V5D1||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2017|
Delta 9 Cannabis Inc. operates as an integrated cannabis company. The company, through its subsidiary, Delta 9 Bio-Tech Inc., engages in the production, distribution, and sale of medical and recreational c ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 00:50|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.